
【Claims】

1. Use of a pharmaceutical composition comprising tegoprazan, which is a compound represented by the chemical formula 1 or a pharmaceutically acceptable salt thereof in amount of 25mg as tegoprazan, in the manufacture of a medicament for the prevention of recurrence of gastroesophageal reflux disease:

[Chemical Formula 1]



2. The use according to claim 1, wherein the pharmaceutical composition is to be administered to a subject, whose gastroesophageal reflux disease have been treated after being diagnosed with the gastroesophageal reflux disease.

3. The use according to claim 2, wherein the subject is one who has been diagnosed of gastroesophageal reflux disease more than or equal to once or twice before administration of the pharmaceutical composition.

4. The use according to claim 2, wherein the subject is one, who does not show a symptom of heartburn and gastric acid reflux due to administration of drug, after being diagnosed with gastroesophageal reflux disease before administration of the pharmaceutical composition.

5. The use according to claim 4, wherein the drug is a gastric-acid secretion inhibitor.

6. The use according to claim 2, wherein the pharmaceutical composition is to be administered to a subject, whose erosive gastroesophageal reflux disease have been treated after being diagnosed with erosive gastroesophageal reflux disease.

7. The use according to claim 6, wherein the subject is one, whose cure of erosive gastroesophageal reflux disease have been identified due to administration of a drug after being diagnosed with the erosive gastroesophageal reflux disease before administration of the pharmaceutical composition.

8. The use according to claim 2, wherein the pharmaceutical composition is to be administered to a subject whose non-erosive gastroesophageal reflux disease has been treated after being diagnosed with non-erosive gastroesophageal reflux disease.

9. The use according to claim 8, wherein the subject is one whose cure of non-erosive gastroesophageal reflux disease has been identified due to administration of a drug after being diagnosed with the non-erosive gastroesophageal reflux disease before administration of the pharmaceutical composition.

10. The use according to claim 1, wherein the pharmaceutical composition is to be administered once a day for 4 to 52 weeks.

11. The use according to claim 1, wherein the pharmaceutical composition is to be administered once a day for 4 to 24 weeks.